The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects

Metabolism: Clinical and Experimental

Volumn 55, Issue 9, 2006, Pages 1149-1154

  Nagel, Jutta M ^a   Tietz, Anne B ^a   Göke, Burkhard ^a   Parhofer, Klaus G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; GLUCOSE; INSULIN; INTERLEUKIN 6; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; TELMISARTAN; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SCREENING; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID ANALYSIS; LIPID METABOLISM; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADIPONECTIN; ADULT; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MIDDLE AGED; OVERWEIGHT; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 33747039772     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.04.011     Document Type: Article

References (18)

1. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
2. Balkau B., Vernay M., Mhamdi L., et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 29 (2003) 526-532
3. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
4. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
5. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
6. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
7. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
8. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
9. Derosa G., Cicero A.F., Bertone G., et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 26 (2004) 1228-1236
10. Derosa G., Ragonesi P.D., Mugellini A., et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27 (2004) 457-464
11. Koulouris S., Symeonides P., Triantafyllou K., et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 95 (2005) 1386-1388
12. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
13. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
14. Cretti A., Lehtovirta M., Bonora E., et al. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur J Clin Invest 31 (2001) 405-416
15. Parhofer K.G., Barrett P.H., and Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab 85 (2000) 4224-4230
16. Vitale C., Mercuro G., Castiglioni C., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4 (2005) 6
17. Clasen R., Schupp M., Foryst-Ludwig A., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
18. Parhofer K.G., Otto C., Geiss H.C., et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2-results of a pilot study. Exp Clin Endocrinol Diabetes 113 (2005) 49-52